A company has acquired Wilmington-headquartered Trial Management Associates, a clinical research firm.

Headlands Research, a multinational network of clinical trial sites, announced the acquisition in a recent news release but did not disclose financial details about the transaction.

With the addition of TMA, the Headlands Research network now includes 21 sites across the United States and Canada, the release stated.

"The acquisition of TMA further demonstrates our commitment to strategic growth," stated Kyle Burtnett, CEO of Headlands Research, in the release. "By adding TMA to our ever-expanding network of clinical trial sites, we are providing sponsors with more geographic options, larger and more diverse participant pools and a greater depth of knowledge in two of our core clinical areas."

In addition to its Wilmington base, TMA has a location in Myrtle Beach, South Carolina.

"Led by President Phil Dattilo, TMA brings significant experience across various therapeutic specialties, including vaccines, endocrinology, and more, complementing Headlands Research's existing areas of focus," according to the release.

Dattilo stated in the release, "The missions of TMA and Headlands Research are synchronous: to improve lives by advancing innovative medical therapies. Joining the Headlands Research family allows TMA to scale our capabilities, share best practices, and combine expertise in ways that will be of great value to our sponsors and participants."

According to the release, Headlands Research has completed more than 5,000 clinical trials.